Feasibility study to determine whether a new generation of catalytic antibodies can be made that overcome existing limitations and are suitable for use in a range of clinical settings

可行性研究以确定是否可以制造出克服现有限制并适合在一系列临床环境中使用的新一代催化抗体

• 批准号: 132132
• 金额: $ 7.65万
• 依托单位: UCB PHARMA LTD
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2016
• 资助国家: 英国
• 起止时间: 2016 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=132132
• 关键词: Feasibility; study; determine; whether; new

Antibodies, produced naturally in our bodies, have been successfully harnessed by the Biopharmaindustry to provide a whole new range of safe and effective treatments for unmet patient need. A goodexample is the anti-TNF antibodies, which are now in common use for suffers of rheumatoid arthritis.Most therapeutic antibodies work by binding to a protein responsible for playing a role in the course ofa disease, thereby stifling its ability to cause harm. This success means that a whole range of attendenttechnologies and know-how has been built-up to support therapeutic antibody R&D. For some timethere has been speculation that if antibodies could be made to work as catalysts ("abzymes") then theycould become even more efficient drugs. This Early Stage Feasibility Study will see scientists at UCB andManchester Institute of Biotechnology collaborate in order to test whether the latest cutting-edgescience is now able to make the breakthrough required for abzymes to at last fulfil their clinical promise.

抗体，在我们的身体中自然产生，已成功地利用Biopolysm maindustry为未满足的患者需求提供了一系列全新的安全有效的治疗方法。一个很好的例子是抗肿瘤坏死因子抗体，现在普遍用于治疗类风湿性关节炎。大多数治疗性抗体通过与一种在疾病过程中起作用的蛋白质结合，从而抑制其造成伤害的能力。这一成功意味着已经建立了一系列的技术和专有技术来支持治疗性抗体的研发。一段时间以来，人们一直在猜测，如果抗体可以作为催化剂（“抗体酶”）工作，那么它们就可以成为更有效的药物。这项早期可行性研究将看到UCB和曼彻斯特生物技术研究所的科学家合作，以测试最新的尖端科学现在是否能够实现抗体酶所需的突破，以最终实现其临床承诺。